It has been suggested that elevated luteal phase prolactin (PRL) levels may have an important role in causing some of the symptoms of the premenstrual tension syndrome (PMTS). Thirty-seven women suffering from severe premenstrual dysphoria were selected for this study. Single morning and afternoon serum PRL evaluations were performed during the follicular (day 9) and late luteal (day 26) phases of the menstrual cycle. PRL was measured by an established double antibody radioimmunoassay technique.
INTRODUCTION
VARIOUS forms of hormonal imbalance have been claimed to be etiologically important in the premenstrual tension syndrome (PMTS). Horrobin 0973) first proposed a major role for hyperprolactinemia and later reviews have considered the evidence in support of this association (Steiner & Carroll, 1977; Carroll & Steiner, 1978) . There are essentially three groups of findings:
(1) Prolactin (PRL) levels tend to be higher in the luteal phase than the follicular phase of the menstrual cycle (Franchimont et al., 1976; Vekemans et al., 1977; Bohnet et ai., 1979) . Serum PRL levels also remain elevated until the onset of menses, unlike estrogen, progesterone, renin, angiotensin, and aldosterone, whose levels begin to fall one week before menses (Frantz, 1979) . This late luteal hyperprolactinemia coincides with the timing of PMTS. (2) PRL levels are elevated in some women with manifestations of PMTS (Halbreich et al., 1976; Horrobin et al., 1976) . However, another study, published after the completion of the work presented herein, showed no differences between mean luteal phase PRL levels of women suffering from PMTS compared to those of controls (Backstrom & Aakvaag, 1981) .
(3) Symptoms of PMTS have been claimed to be markedly ameliorated by bromocriptine, a PRL suppressant (Benedek-Jaszmann & Hearn-Sturtevant, 1976 ). However, other investigators have failed to replicate these findings (Andersen et al., 1977; Ghose & Coppen, 1977; Andersch et al., 1978; Graham et al., 1978) .
The present study was designed to further investigate the postulated role of PRL in PMTS.
METHODS
Subjects for this study were 37 adult women (ages 22-42 years) who complained of a severe dysphoric syndrome in the premenstruum, but who showed no evidence of emotional disorder at other times. Their premenstrual dysphoric symptoms bad been present for at least six consecutive menstrual cycles. They showed no abnormality on physical examination, and all had normal routine laboratory values. Their six previous menstrual cycles had been regular, and they were completely drug-free for at least four weeks before entering the study.
After giving informed consent, all subjects were evaluated twice during the menstrual cycle. This occurred during a follicular phase visit on day 9 (day I = onset of menses) and a lutcai phase visit, on or around day 26, but always two to six days premenstrual, counting back from the first day of menses. The clinical severity of the symptoms and the on/off nature of the phenomena were assessed by several observer and self-rating scales (Haskett et al., 1980; Steiner et al., 1980) . Single PRL levels were obtained from all 37 womea at 1600 hr during both the follicular (day 9) and late luteal phases (day 26). In 21 of the subjects a 1000 hr PRL sample alsowas taken.
In addition, two subjects with extremely severe PMTS and two asymptomatic healthy female controls participated in a study of 24-hr PRL secretion patterns. These women were admitted to the Clinical Research Center on days 9 and 26 of their menstrual cycles. The follicular phase (day 9) studies preceded the iutcal phase (day 26) studies in all subjects. Blood samples were collected every 30 min for 26 hr from an indwelling catheter in the antecubital vein. Severity of symptoms was established by using the Menstrual Distress Questionnaire; Form-T (MDQ-T) (Moos, 1969) . The MDQ is a 47 symptom scale with a score of I to 6 [i.e. 1 = no symptoms at all (minimum total score = 47); 6 = extremely disabling (maximum total score = 282)]. The Form-T (Today) is rated according to the presence of each symptom on the day of completing the scale.
Thirty subjects participated in a treatment trial of bromocriptine (CB-IS4) and received doses ranging from 2.5 to 7.5 mg daily. The trial was a double-blind placebo controlled design. Subjects received medication or placebo from day 10 until the onset of menses for three consecutive cycles. Details of the clinical responses to this treatment are reported separately (Steiner et al., 1983) . Serum PRL levels were estimated in !0 women taking 2.5, 5.0 or 7.5 mg bromocriptine daily, The blood samples were drawn between 0900 and 1200 hr on days 9 and 26 of a pretreatment cycle (cycle 0) and for each of the three cycles of the trial (cycles 1 -3). Serum PRL was measured by an established double antibody radioimmunoassay technique , with intra-assay variability of 8.9070, inter-assay variability of 13.8070, and sensitivity of 0.1 ng/tube. Human PRL (hPRL, AFP 1562-C) for iodination and standard was kindly provided by Dr. Albert F. Parlow. lodination was performed according to the glucose oxidase -lactoperoxidase method (Tower et al., 1977) , and the suitability of the '251-PRL was verified by the talc -resin -TCA technique (Tower et al., 1978) . Anti-hPRL (AFP-I) was supplied by the National Pituitary Agency. Values are reported as ng/ml of hPRL AFP 1562.C (Hays & Rubin, 1979) . The data were analyzed by two-tailed t-test and analysis of variance with repeated measures.
RESULTS
The values obtained for the serum PRL estimations during the two phases of the menstrual cycle are shown in Fig. 1 afternoon (1600 hr) samples during either phase of the cycle. No significant difference was found between follicular and late luteal mean PRL levels at 1000 hr. There was, however, a significant increase in mean PRL levels at 1600 hr from follicular to late luteal phase (p < 0.05; two-tailed t-test). Although statistically significant, the implications of this finding are unclear. One-third of the subjects (12 of the 37 women sampled at 1600 hr and six of the 21 sampled at 1000 hr) showed lower PRL levels during the late luteal (premenstrual) phase than during the follicular phase. There was no obvious clinical difference between women who had increased and those who had decreased late luteal phase PRL levels. Mean serum PRL levels from the two women with severe PMTS who participated in the 24-hour catheter studies are shown in Table I . In one subject (No. 1), her mean PRL level in the late luteal (premenstrual) phase, recorded when she was severely affected by symptoms of PMTS (with an extremely high MDQ-T total score of 194), was higher than her mean PRL level in the follicular phase. A much smaller change was seen in the other subject (No. 2), who also was markedly symptomatic, with a very high MDQ-T total score of 171. Table I also shows the mean PRL levels from the asymptomatic control subjects. It is notable that, although both subjects denied any features of PMTS, also evidenced by their minimal scores on the MDQ-T, subject No. 4 had a marked elevation of her mean PRL level in the late luteal (premenstrual) phase. This woman stated that her menses appeared each month with absolutely no preceding emotional or somatic changes, and no behavioural aspects of PMTS were apparent during the study. Table II shows the serum PRL levels for 10 subjects measured during the follicular and late luteal (premenstrual) phases of four menstrual cycles, a pretreatment cycle (cycle 0) and three cycles of treatment (cycles l-3). Subjects were taking bromocriptine when sampled on day 26 of cycles l -3, and all medication was discontinued on day l of the following cycles. As shown, bromocriptine suppressed PRL on day 26, but the mean serum PRL levels on day 9 were significantly elevated (p < 0.004; ANOVA, repeated measures). Despite this marked "rebound" hyperprolactinemia following the cessation of bromocriptine, all subjects remained free of symptoms, with no observable effects on mood, behaviour or menstrual regularity.
DISCUSSION
Our data failed to show any specific relationship between serum PRL levels and PMTS. Even though there was a slight premenstrual increase of PRL, neither the PRL measurements from single blood samples nor the 24-hr PRL secretion profiles support the hypothesis that PMTS is associated with an elevation in serum PRL levels. As mentioned, similar results have been reported by Backstrom & Aakvaag (1981) .
Some very high PRL levels were recorded in this study, at times when women reported being completely free of symptoms. In particular, the "rebound" hyperprolactinemia which followed the cessation of bromocriptine coincided with an interval of marked relief from PMTS symptoms. The lack of emotional or behavioural changes during a "rebound" hyperprolactinemia has not been reported before, to our knowledge.
The assessment of PRL levels in patients with PMTS is particularly difficult. The secretion of PRL is pulsatile, and serum levels fluctuate with repeated measures over intervals of a few minutes. PRL also is released after emotional or physical stress (Noel et ai., 1972) . We tried to minimize this effect in our 24-hr catheter studies by sampling all subjects during the follicular phase prior to the late luteal (premenstrual) sampling. The PRL levels obtained from single blood samples should, nevertheless, be interpreted cautiously.
The 24-hr PRL profiles from the subjects in this study showed great variation and no obvious relationship to PMTS or menstrual cycle phase. One other study of 24-hr PRL profiles in an asymptomatic subject, measuring episodic release and diurnal variation, showed an increase in nocturnal PRL release at midcycle or the time of ovulation (Ehara et al., 1973) . Other stimuli of PRL secretion include meals and changes in ambient temperature (Quigley et ai., 1981; Mills & Robertshaw, 1981) . Previous studies have not controlled for these variables, and it is now obvious that future studies should.
Finally, even if PRL secretion can be shown to be associated with the clinical features of PMTS, this hormone may be serving as an endocrine reflection of central neurotransmitter activity rather than as a direct etiological agent for these symptoms. Many of the transmitters which influence the activity of the hypothalamic-pituitarygonadal (HPG) axis during the normal menstrual cycle are also believed to alter the secretion of PRL, e.g. dopamine and endogenous opiates. The timing of PMTS symptoms makes it a reasonable hypothesis that they are related to the cyclical neuroendocrine changes in the HPG axis, so that it is possible that changes in PRL, estrogens or progesterone, which are an important part of the menstrual cycle, have an indirect, still unclear relationship to PMTS.
